RxDoctor Payments Data

Beth Schultz, PA

Physician Assistant · Winchester, VANPI 1881967255

Payments from drug & device makers

$5,959in general payments, 2019–2025

Across 385 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • AbbVie$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$523
  • Phathom Pharmaceuticals, Inc.$464
  • Gilead$357
  • Ardelyx, Inc.$316
  • plus $2K from 22 others

What the payments were for

  • Food & beverage$5,959100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,959 in reported general payments places this provider in the 90th percentile of 3,376 physician assistant providers in Virginia.

See all physician assistant providers in Virginia

Medicare billing

Part B allowed, 2024
$56,530
Medicare patients
359
Services billed
555

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab36$981,626
EpclusaSofosbuvir/Velpatasvir21$527,484
Humira(Cf) PenAdalimumab12$192,626
CreonLipase/Protease/Amylase19$78,358
LinzessLinaclotide70$65,724
Mesalamine23$16,286
TrulancePlecanatide17$12,453
Mesalamine DrMesalamine18$11,522
Sucralfate34$7,865
Budesonide DrBudesonide16$7,532
Dexlansoprazole DrDexlansoprazole31$5,790
Lubiprostone47$5,414
Colesevelam Hcl27$5,095
Pantoprazole Sodium345$4,487
Dicyclomine Hcl121$3,932

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$189$981,62636 claims
GileadEpclusa$357$527,48421 claims
AbbVieCreon, Linzess$1,030$144,08289 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$1,192$12,45317 claims
SandozLansoprazole$27$1,59433 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,376 physician assistant providers in Virginia.

Other physician assistant in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →